Skip to main content

Novartis Value Stock - Dividend - Research Selection

Novartis

ISIN: CH0012005267 , WKN: 904278

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company\'s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

2025-03-28

5 Reasons To Buy Regenxbio Right Now

2025-03-26
Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.

Wasatch Global Value Fund Q4 2024 Commentary

2025-03-24
The Wasatch Global Value Fund—Investor Class returned -5.78% in the fourth quarter of 2024, underperforming the MSCI AC (All Country) World Value Index, which lost -4.71%.

Lantheus Holdings: One Blockbuster, Evolving Pipeline

2025-03-23
Lantheus Holdings' stock surges on strong Q4, driven by Pylarify's $1B revenue and strategic growth moves.

Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy

2025-03-21
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.

Harrow: A Name I Am Accumulating

2025-03-19
Harrow, Inc. stock dropped 50% post-3Q24, but Q4 previews and FY2025 projections signal growth potential. Click for my updated look at HROW stock prospects.

BlackRock Advantage International Fund Q4 2024 Commentary

2025-03-18
The fund posted returns of -6.71% (Institutional shares) and -6.78% (Investor A shares, without sales charge) for the fourth quarter of 2024. Read more here.

Why Organon Is A Top Pick For Income Investors

2025-03-17
In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.

Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)

2025-03-11
Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.

54 Upcoming Dividend Increases, Including A King

2025-03-08
My strategy focuses on companies with consistent dividend growth and outperforming benchmarks. Check out this week's dividend increases.